PCRX holder plans sale of 13,137 shares

A holder of PCRX common stock filed a notice to sell 13,137 shares under Rule 144.

Rhea-AI Filing Summary

A holder of PCRX common stock filed a notice to sell 13,137 shares under Rule 144. The shares are common stock to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/02/2026 and aggregate market value of 269,702.61.

The securities were acquired as restricted stock vesting from the issuer on 02/01/2026, treated as compensation. The filing notes that there were 43,021,275 shares of this class outstanding at the time, providing baseline context for the planned sale size.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCRX shares are planned to be sold under this Rule 144 filing?

The filing covers a planned sale of 13,137 shares of PCRX common stock. These shares have an aggregate market value of 269,702.61 and are expected to be sold through Fidelity Brokerage Services LLC on the NASDAQ around 02/02/2026.

How were the PCRX shares in this Rule 144 notice originally acquired?

The PCRX shares were acquired via restricted stock vesting from the issuer on 02/01/2026. The filing identifies the nature of payment as compensation, indicating these 13,137 common shares were received as part of a compensation arrangement rather than a cash purchase.

What is the aggregate market value of the PCRX shares to be sold?

The 13,137 PCRX common shares listed in the notice have an aggregate market value of 269,702.61. This total reflects the market value at the time of the filing and helps investors gauge the approximate dollar size of the planned Rule 144 stock sale.

On which exchange and through which broker will the PCRX shares be sold?

The shares are planned to be sold on the NASDAQ through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917. Using a major brokerage and national exchange indicates a standard open-market transaction structure for this Rule 144 sale.

How many PCRX shares of this class were outstanding when the sale was planned?

The filing states that 43,021,275 shares of this class of PCRX common stock were outstanding. This figure provides baseline context for the planned 13,137-share sale, allowing investors to compare the transaction size relative to the total outstanding share count.

What dates are important in this PCRX Rule 144 filing?

Key dates include 02/01/2026, when 13,137 shares vested as restricted stock compensation, and 02/02/2026, the approximate date of sale on NASDAQ. These dates link the acquisition event and the planned disposition under Rule 144 for PCRX shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 10:55 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001296965
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Pacira BioSciences, Inc.
SEC File Number	001-35060
Address of Issuer	2000 SIERRA POINT PARKWAY SUITE 900 BRISBANE CALIFORNIA 94005
Phone	650-242-8052
Name of Person for Whose Account the Securities are To Be Sold	WILLIAMS KRISTEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	13137	269702.61	43021275	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted Stock Vesting	Issuer			13137	02/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Kristen M. Williams
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)